Evidence map›Paper›PMID 39811280›Full record

ArticleHeliyon2025

Evaluation of neutralizing antibody titers against SARS-CoV-2 JN.1 omicron subvariant during pregnancy - A case series study.

Marie Didembourg, Clara David, Laure Morimont, Eva Cransquint, Julien Favresse, Jonathan Douxfils, Constant Gillot

Abstract read
In one paragraph

Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marie DidembourgClinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, University of Namur, 5000, Namur, Belgium.
Clara DavidQualiblood s.a., Research and Development Department, Liège, Belgium.
Laure MorimontClinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, University of Namur, 5000, Namur, Belgium.
Eva CransquintClinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, University of Namur, 5000, Namur, Belgium.
Julien FavresseClinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, University of Namur, 5000, Namur, Belgium.
Jonathan DouxfilsClinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, University of Namur, 5000, Namur, Belgium.
Constant GillotClinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, University of Namur, 5000, Namur, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: SARS-CoV-2 infection during pregnancy poses health risks to both mother and fetus. This study investigates neutralizing antibodies (NAbs) against the SARS-CoV-2 JN.1 Omicron subvariant in pregnant women, focusing on responses to natural infection, vaccination, and passive immunity. Methods: A single-center, prospective study collected blood samples from 19 pregnant women at various pregnancy stages and postpartum. NAb titers were analyzed using a pseudovirus neutralization assay, with statistical analyses (p-value <0.05) conducted using unpaired Results: Among participants, 63.2 % had at least one positive NAb titer, with only one vaccinated case. No significant difference in NAb titers was found between symptomatic and asymptomatic women. NAbs were detected in cord blood, especially when infection or vaccination occurred close to delivery, indicating passive immunity transfer to the newborn. Conclusion: NAb titers change dynamically during pregnancy, increasing then decreasing. Most pregnant women were asymptomatic and NAbs were effectively transferred to the fetus when infection or vaccination occurred near delivery. These findings highlight the importance of vaccination timing, suggesting late second or third trimester vaccination may provide better protection, emphasizing the need for adherence to vaccination guidelines to optimize maternal and neonatal immunity.

Indexed as

Maternal immunityNeutralizing antibodiesPassive immunityPregnancySARS-CoV-2

Identifiers

PMID39811280
PMCPMC11729664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.